FDA Expands Ilumya Approval to Include Active Psoriatic Arthritis

Sun Pharma's Ilumya (tildrakizumab-asmn), an interleukin-23 (IL-23) inhibitor, has received FDA approval for adults with active psoriatic arthritis. This decision adds a second indication to the drug's label, expanding its use from moderate-to-severe plaque psoriasis into rheumatology.